<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68810">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01902940</url>
  </required_header>
  <id_info>
    <org_study_id>CCFDN-IBM-2013</org_study_id>
    <secondary_id>CCFDN-IBM-2013</secondary_id>
    <nct_id>NCT01902940</nct_id>
  </id_info>
  <brief_title>Natural History in CCFDN and IBM Syndromes</brief_title>
  <official_title>Retrospective Cohort Study Assessing the Natural Course in Congenital Cataract Facial Dysmorphism Neuropathy Syndrome (CCFDN) and Sporadic and Hereditary Inclusion Body Myopathies (IBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      So far, only limited data is available regarding the natural course in Congenital Cataract
      Facial Dysmorphism Neuropathy Syndrome (CCFDN) and sporadic and hereditary inclusion body
      myopathies (IBM). Several criteria and outcome measures have led to contradicting results.
      The investigators want to retrospectively assess the natural course of the disease in CCFDN
      and IBM patients according to the data recorded during clinical routine visits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We wanted to assess the natural course in Congenital Cataract Facial Dysmorphism Neuropathy
      Syndrome (CCFDN) and sporadic and hereditary inclusion body myopathies (IBM) over 10 years
      to gain new insights in both conditions.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Manual Muscle Strength assessed by Medical Research Council (MRC)</measure>
    <time_frame>6-months intervals</time_frame>
    <safety_issue>No</safety_issue>
    <description>Retrospective</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Inclusion Body Myositis, Sporadic</condition>
  <condition>Inclusion Body Myopathy, Autosomal-recessive</condition>
  <condition>Inclusion Body Myopathy, Autosomal-dominant</condition>
  <condition>Congenital Cataracts, Facial Dysmorphism, And Neuropathy</condition>
  <arm_group>
    <arm_group_label>Natural History</arm_group_label>
    <description>Assessment of natural history in IBM and CCFDN</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Natural History</intervention_name>
    <description>Assessment of natural history in IBM and CCFDN</description>
    <arm_group_label>Natural History</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CCFDN and IBM
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and/or genetic diagnosis of Congenital Cataract Facial Dysmorphism
             Neuropathy Syndrome (CCFDN) and sporadic and hereditary inclusion body myopathies
             (IBM)

        Exclusion Criteria:

          -  Additional neuromuscular diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maggie C Walter, MD, MA</last_name>
    <role>Study Chair</role>
    <affiliation>Friedrich-Baur-Institute, Dept. of Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friedrich-Baur-Institut, Ludwig-Maximilians-University of Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 17, 2013</lastchanged_date>
  <firstreceived_date>July 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Maggie Walter</investigator_full_name>
    <investigator_title>Professor, MD, MA</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Myositis, Inclusion Body</mesh_term>
    <mesh_term>Contracture</mesh_term>
    <mesh_term>Ophthalmoplegia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
